$38.9 M

IPIX Mkt cap, 08-Oct-2018
Innovation Pharmaceuticals Net income (FY, 2018)-16.4 M
Innovation Pharmaceuticals EBIT (FY, 2018)-13.9 M
Innovation Pharmaceuticals Cash, 30-Jun-20182.4 M

Innovation Pharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

R&D expense

6.3m10.5m9.0m12.8m11.4m

General and administrative expense

872.0k1.2m1.9m1.3m1.4m

Operating expense total

8.0m13.0m12.7m15.3m13.9m

EBIT

(8.0m)(13.0m)(12.7m)(15.3m)(13.9m)

Interest expense

210.0k202.0k202.0k202.0k202.0k

Interest income

1.0k4.0k4.0k2.0k1.0k

Pre tax profit

(8.2m)(13.1m)(12.9m)(15.5m)(16.4m)

Net Income

(8.2m)(13.1m)(12.9m)(15.5m)(16.4m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

R&D expense

1.9m2.3m1.8m2.1m3.0m2.3m2.7m3.2m1.8m

General and administrative expense

244.0k275.0k339.0k352.0k249.0k362.0k344.0k331.0k295.0k

Operating expense total

2.2m2.6m2.2m3.3m3.7m3.0m3.3m3.9m2.4m

EBIT

(2.7m)(2.8m)(2.5m)(3.3m)(3.7m)(3.0m)(3.3m)(3.9m)(2.4m)

Interest expense

51.0k51.0k51.0k50.0k51.0k51.0k50.0k51.0k51.0k

Interest income

1.0k1.0k1.0k1.0k1.0k1.0k1.0k

Pre tax profit

(2.8m)(2.9m)(2.6m)(3.3m)(3.7m)(3.0m)(3.4m)(3.9m)(2.4m)

Net Income

(2.8m)(2.9m)(2.6m)(3.3m)(3.7m)(3.0m)(3.4m)(3.9m)(2.4m)

Innovation Pharmaceuticals Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

5.0m8.4m6.3m4.1m2.4m

Current Assets

5.6m8.8m6.7m4.5m2.6m

Total Assets

10.9m14.3m11.4m9.1m6.5m

Accounts Payable

42.2m

Current Liabilities

9.6m7.3m8.5m10.6m8.7m

Total Liabilities

9.6m7.3m8.5m10.6m8.7m

Additional Paid-in Capital

29.2m48.2m57.0m68.3m83.7m

Retained Earnings

(28.0m)(41.2m)(54.0m)(69.6m)(85.9m)

Total Equity

1.2m7.0m3.0m(1.5m)(2.2m)

Financial Leverage

9 x2 x3.9 x-6.2 x-3 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

Cash

7.1m9.5m10.8m7.8m6.2m5.3m5.6m3.9m5.6m1.3m

Current Assets

7.2m9.6m11.4m8.0m6.4m5.8m6.2m4.1m5.7m1.5m

Total Assets

12.5m14.9m17.1m13.5m11.9m11.3m10.9m8.8m10.5m5.8m

Current Liabilities

8.0m7.7m7.3m7.5m7.6m8.4m8.8m8.7m9.3m9.5m

Total Liabilities

7.6m8.4m8.8m8.7m9.3m9.5m

Additional Paid-in Capital

36.9m42.3m47.8m49.8m51.3m53.6m59.2m60.5m65.5m77.3m

Retained Earnings

(32.4m)(35.2m)(38.1m)(43.7m)(47.1m)(50.8m)(57.0m)(60.4m)(64.3m)(81.1m)

Total Equity

4.5m7.1m9.8m6.0m4.3m2.9m2.1m136.0k1.2m(3.7m)

Financial Leverage

2.8 x2.1 x1.7 x2.2 x2.8 x3.9 x5.1 x64.6 x8.9 x-1.5 x

Innovation Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(8.2m)(13.1m)(12.9m)(15.5m)(16.4m)

Accounts Payable

815.0k(826.0k)1.7m1.2m(1.5m)

Cash From Operating Activities

(7.5m)(13.1m)(9.9m)(11.7m)(13.3m)

Purchases of PP&E

(43.0k)(9.0k)(68.0k)

Cash From Investing Activities

(2.6m)(459.0k)(414.0k)(336.0k)(104.0k)

Cash From Financing Activities

12.2m17.0m8.2m9.9m11.7m

Interest Paid

259.0k366.0k235.0k44.0k171.0k

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(2.8m)(2.9m)(2.6m)(5.9m)(9.6m)(3.0m)(3.4m)(3.9m)

Accounts Payable

259.0k1.3m

Cash From Operating Activities

(4.6m)(7.7m)

Purchases of PP&E

(68.0k)

Cash From Investing Activities

(217.0k)(348.0k)

Cash From Financing Activities

2.6m5.0m

Interest Paid

29.0k74.0k

Innovation Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

-3 x
Report incorrect company information